Premium
ZP1609/danegaptide and mitochondrial connexin hemichannels: a harbinger for peptide drug design
Author(s) -
DeLalio Leon J,
Isakson Brant E
Publication year - 2017
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.13891
Subject(s) - connexin , mitochondrion , gap junction , chemistry , pharmacology , drug , microbiology and biotechnology , medicine , biology , biochemistry , intracellular
This article is a Commentary on Boengler K, Bulic M, Schreckenberg R, Schlüter K-D, Schulz R (2017). The gap junction modifier ZP1609 decreases cardiomyocyte hypercontracture following ischaemia/reperfusion independent from mitochondrial connexin 43. Br J Pharmacol 174: 2060-2073. https://doi.org/10.1111/bph.13804.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom